Relypsa (RLYP): Veltassa's Path To Preferred Hyperkalemia Treatment - Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Relypsa's (RLYP) Veltassa Expected to Benefit from Delay to AstraZeneca's (AZN) ZS-9 - BTIG
June 2, 2016 7:47 AM EDTBTIG affirms Relypsa (Nasdaq: RLYP) at Buy with a price target of $35 following recent conversations with management.
Analyst Timothy Chiang commented, We recently hosted a Q&A session with Relypsas senior management team to discuss a number of key items including the recent CRL... More
Mizuho Securities Upgrades Relypsa (RLYP) to Neutral; Strengthened Veltassa Launch and Higher Probability of a Takeout
June 1, 2016 6:18 AM EDTMizuho Securities upgraded Relypsa, Inc. (NASDAQ: RLYP) from Underperform to Neutral with a price target of $20.00 (from $12.00).
Analyst Irina Koffler commented, "Relypsa's stock is benefiting from a regulatory delay of competitor AZN, which gives Relypsa more time to strengthen its Veltassa launch and explore strategic alternatives. With the recent run-up, we believe shares are fairly valued and upgrade the stock to Neutral from... More
